Butts RJ, et al. - Study authors attempted to compare 2 common induction strategies, basiliximab and ATG. They performed analysis of the ISHLT transplant registry. From January 1, 2000, to June 30, 2015, the database was queried for pediatric heart transplants who had received induction with basiliximab or ATG. Graft survival was the primary end-point. One-year survival and 1-year conditional survival were the included secondary end-points. No difference was found in graft loss in the basiliximab cohort compared to the ATG cohort. In the antithymocyte cohort, infection prior to discharge was more common. Findings revealed that induction with ATG was linked with improved late graft survival compared to basiliximab.